ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 049

Levels of Anxiety and Depressive Symptoms in Juvenile Idiopathic Arthritis (JIA) and Their Correlation to Disease Manifestations Using Patient-Reported Outcomes Measurement Information System (PROMIS®) Measures

Danielle Fair1, Judyann Olson 2, Jan Lemke 3, Stella Protopapas 4, Ke Yan 5 and Jian Zhang 6, 1Medical College of Wisconsin & Affiliated Hospitals: Children's Wisconsin, Wauwatosa, Wisconsin, 2Medical College of Wisconsin: Children's Wisconsin, Wauwatosa, Wisconsin, 3Children's Wisconsin, Milwaukee, Wisconsin, 4Riley Children’s Hospital at Indiana University, Indianapolis, Indiana, 5Medical College of Wisconsin, Milwaukee, Wisconsin, 6Medical College of Wisconsin, 53226, Wisconsin

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: Anxiety, depression, juvenile idiopathic arthritis (JIA), PROMIS

  • Tweet
  • Email
  • Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Thursday, April 30, 2020

Title: Poster Session 1

Session Type: ACR Abstract Session

Session Time: 6:00PM-7:00PM

Background/Purpose: Children with chronic diseases have higher rates of mental health issues and less favorable outcomes than the general pediatric population.  Children with JIA experience pain and limited mobility which may affect their mental health.  Prior studies of mental health and the relationship to disease manifestations in JIA have had variable results, partly due to a lack of a standard assessment tool.  PROMIS has recently been developed to help standardize and validate assessments on patient-reported outcomes.  The aims of this study are to describe the levels of anxiety and depressive symptoms in JIA patients using PROMIS measures and examine the association with disease manifestations.

Methods: We conducted a two-center, cross-sectional study of 87 JIA patients and their parents.  JIA ILAR subtypes included: 36% oligoarticular (52% extended; 48% persistent), 32% polyarticular (82% RF –; 18% RF +), 7% systemic, 5% psoriatic, 3% enthesitis-related, and 17% undifferentiated.  Patients and parents completed PROMIS surveys in depression, anxiety, psychological stress, and pain domains to assess psychosocial functioning and the Childhood Health Assessment Questionnaire (CHAQ) to assess physical functioning.  Disease activity was determined by the clinical juvenile arthritis disease activity score (cJADAS10).  T-scores are calculated for PROMIS measures (mean=50; standard deviation=10).  PROMIS defines T-scores for depressive and anxiety symptoms as T-score < 50 = normal, T-score 50 – < 55 = mild, T-score 55 – < 65 = moderate, and T-score ≥ 65 = severe.  The Pearson’s correlation and Kruskal-Wallis tests were used to determine the relationship between mental health PROMIS T-scores and disease manifestations.

Results: Eighty-six JIA patients completed the study; 76% female, 86% Caucasian, and median age of 14 years. Patients had a median active joint count of 0 joints (range 0-11) and a median cJADAS10 score of 2 (range 0-23). The median CHAQ score was 0 (range 0-1.75) (Table 1). Using the cJADAS10, disease activity was classified as 49% inactive, 21% low, 25% moderate, and 5% high (Table 2). The mean PROMIS T-scores for depressive and anxiety symptoms were significantly lower in JIA patients compared to the general pediatric population (p< 0.0001). One patient (1.2%) had severe symptoms, and 15 patients (17.4%) had moderate symptoms in the PROMIS depressive domain. Two patients (2.3%) had severe symptoms, and 13 patients (15.1%) had moderate symptoms in the PROMIS anxiety domain (Table 3). The correlations between depressive (r=0.66; p< 0.0001) and anxiety (r=0.49;p< 0.0001) symptoms with pain interference were significantly different from zero. Total active joint count and cJADAS10 scores did not correlate with depressive or anxiety symptoms.

Conclusion: Using PROMIS, 36% of JIA patients had moderate to severe symptoms of anxiety and/or depression. JIA patients in our study experienced less anxiety and depressive symptoms compared to healthy children. Levels of depressive and anxiety symptoms in JIA patients are associated with pain, but they are not associated with disease activity markers such as total active joint count or cJADAS10 scores.

Table 1. Demographic, Treatment, and Disease Characteristic Data

Table 2. JIA Disease Activity based on cJADAS10 scores

Table 3. PROMIS Mental Health Results


Disclosure: D. Fair, None; J. Olson, None; J. Lemke, None; S. Protopapas, None; K. Yan, None; J. Zhang, None.

To cite this abstract in AMA style:

Fair D, Olson J, Lemke J, Protopapas S, Yan K, Zhang J. Levels of Anxiety and Depressive Symptoms in Juvenile Idiopathic Arthritis (JIA) and Their Correlation to Disease Manifestations Using Patient-Reported Outcomes Measurement Information System (PROMIS®) Measures [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/levels-of-anxiety-and-depressive-symptoms-in-juvenile-idiopathic-arthritis-jia-and-their-correlation-to-disease-manifestations-using-patient-reported-outcomes-measurement-information-system-promis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/levels-of-anxiety-and-depressive-symptoms-in-juvenile-idiopathic-arthritis-jia-and-their-correlation-to-disease-manifestations-using-patient-reported-outcomes-measurement-information-system-promis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology